KEC International secures new orders worth Rs 1,034 crore across civil, T&D, and cable businesses
By Aditya Bhagchandani Published on May 12, 2025, 14:54 IST
KEC International Ltd., a global EPC major and part of the RPG Group, announced on Monday that it has secured new orders worth Rs 1,034 crore across multiple business segments. These wins mark a strong start to the financial year and include breakthrough orders in the semiconductor and STATCOM segments. Order Breakdown: Transmission & Distribution (T&D): STATCOM project from a global OEM in India Supply of towers, hardware, and poles in the Americas
Civil: Establishing a semiconductor plant for a private player in India (first-time entry into this segment) An upstream project for a leading Indian steel manufacturer
Cables: Supply of various types of cables across India
Vimal Kejriwal, MD & CEO of KEC International, stated:
'We are pleased to begin the financial year with prestigious order wins in emerging and high-growth segments… These strategic orders reinforce our confidence in achieving the targeted order intake for the year and reflect our continued progress in deepening and solidifying our business portfolio.'
This order marks KEC's first foray into the STATCOM space, a key milestone in expanding its substation capabilities, and strengthens its presence in civil infrastructure—particularly in semiconductors and metals & mining.
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
5 hours ago
- Time Business News
How Debt Settlement Companies Help Reduce Loan Burden
In today's uncertain financial climate, thousands of individuals are drowning under the weight of unsecured loans and credit card debt. Mounting EMIs, relentless recovery agent calls, and the fear of legal action can push anyone to the edge. But there is a powerful, legal, and structured solution that offers relief — Debt Settlement. At Settle Loan, we specialize in turning your financial crisis into a controlled, manageable process. Our mission is simple: to help you settle your loan burden through expert negotiation, legal intervention, and ethical resolution strategies. What Is Debt Settlement? Debt settlement is a legal and negotiated agreement between a borrower and a lender where the borrower pays a reduced lump-sum amount to clear the entire loan. This is not a loan, but a full and final settlement of dues at a significantly lower amount than originally owed. It is the ideal solution for borrowers who: Are unable to keep up with EMI payments Are facing continuous harassment from recovery agents Have defaulted due to job loss, medical emergency, or personal crisis Want a dignified and legal closure to their debt problems How Settle Loan Helps You Reclaim Your Financial Freedom Evaluating Your Financial Health – The debt settlement journey begins with a careful review of your financial status: A breakdown of all your existing loans and credit card dues An overview of your income and living expenses An estimation of what you can reasonably afford to pay, either as a lump sum or in parts Communicating with Lenders – Settlement experts step in to negotiate on your behalf: They approach banks, NBFCs, and card companies They work to reduce your total outstanding amount—often by 30% to 60% Their aim is to secure an agreement that clears your dues in a single reduced payment Shielding You from Harassment – Many firms offer legal protection against recovery agent abuse: They intervene to stop calls and threats They issue legal warnings to lenders and agents They help enforce your rights under Indian financial regulations Documentary and Legal Assistance – The settlement firm ensures all paperwork is in order: Drafting legal agreements and No Dues letters Securing proper documentation to avoid future legal or credit issues Supporting the correction of unjust negative entries in your credit report CIBIL Score Support – A good agency also helps you bounce back: They offer expert advice on restoring your credit score They provide financial strategies to prevent recurring debt Bankruptcy Prevention – Debt settlement is a more private, less destructive option than insolvency: You avoid court proceedings and legal declarations You maintain control over the process You can repay your debts on your own terms with dignity Take the First Step Toward Freedom If you're stuck, don't stay silent. Let Settle Loan be your voice and your shield. We're not just TIME BUSINESS NEWS
Business Wire
8 hours ago
- Business Wire
Torrent Pharma to Acquire Controlling Stake in J. B. Chemicals & Pharmaceuticals from KKR
MUMBAI, India--(BUSINESS WIRE)--Torrent Pharmaceuticals Limited ('Torrent') and global investment firm KKR today announced that Torrent has entered into definitive agreements to acquire controlling stake in J. B. Chemicals and Pharmaceuticals ('JB Pharma') from KKR at an Equity Valuation of INR 25,689 crores (on fully diluted basis), followed by a merger of the two entities. The transaction marks a significant step in Torrent's ambition to create a future-ready, diversified healthcare platform combining a deep chronic segment heritage with emerging international CDMO capabilities. The transaction will be executed in 2 phases: Acquisition of 46.39% equity stake (on a fully diluted basis) through a Share Purchase Agreement ('SPA') at a consideration of INR 11,917 crores (INR 1,600 per share) followed by a mandatory open offer to acquire up to 26% of JB Pharma shares from public shareholders at an open offer price of INR 1,639.18 per share. In addition to the above, Torrent has also expressed its intent to acquire up to 2.80% of equity shares from certain employees of JB Pharma at the same price per share as KKR. Merger between Torrent and JB Pharma through a scheme of arrangement. As per the approval given by the Board of Directors of both companies, upon merger of JB Pharma with Torrent, every shareholder holding 100 shares in JB Pharma shall receive 51 shares of Torrent. Samir Mehta, Executive Chairman, Torrent, commented: 'We are pleased to have on board the JB Pharma heritage and build on the platform for the future. Torrent's deep India presence and JB Pharma's fast growing India business, combined with the CDMO and international footprint offers immense potential to scale both revenue and profitability. This strategic alignment furthers our goal of strengthening our presence in the Indian pharma market, and build a larger diversified global presence. Moreover, the CDMO platform provides a new long-term avenue of growth for Torrent.' Gaurav Trehan, Co-Head of Asia Pacific and Head of Asia Pacific Private Equity, KKR, and CEO of KKR India, said: 'JB Pharma's transformation under our stewardship is a testament to KKR's ability to scale high-quality companies. We are proud to have collaborated with JB Pharma's management team, led by Nikhil Chopra, to bring the breadth of KKR's global experience and operational expertise to support the company's organic and inorganic growth, and help JB Pharma become one of India's fastest growing branded pharmaceutical companies. We believe the company is well-positioned for continued growth ahead and wish the team every success in its next chapter with Torrent.' Nikhil Chopra, Chief Executive Officer and Whole Time Director of JB Pharma, remarked: 'Over the past five years, JB Pharma has emerged as one of India's fastest growing pharmaceutical players, owing to KKR's strategic guidance, stewardship of our independent directors and a focused strategic and executional excellence by the management team. We have built a strong foundation to deliver market-leading growth, as well as consistent improvement in profitability in the medium and long term. As we now enter a new chapter alongside Torrent Pharmaceuticals, we are confident that the combined strengths of our organizations will unlock greater opportunities to enhance healthcare access across our markets.' Strategic Rationale for Acquisition Acquisition provides access to a fast-growing India franchise, with leading brands in the chronic segment, and entry into untapped therapeutic areas like ophthalmology Strengthens market share in the IPM for Torrent Operational synergies across multiple business functions Platform diversification: entry into the CDMO segment with long-term potential Consolidation in key international markets and greater ability to scale up Transaction Structure & Approvals Torrent will acquire 46.39% stake (on a fully diluted basis) through an SPA and additional potential acquisition of up to 2.80%, aggregating to 49.19% which will trigger a mandatory open offer of 26.0% as per Regulation 3 and 4 of SEBI (SAST) Regulations followed by a merger through a Scheme. Both the SPA and Scheme are subject to standard requisite statutory and regulatory approvals, including from Securities and Exchange Board of India (SEBI), Stock Exchanges, the Competition Commission of India (CCI), National Company Law Tribunal (NCLT), and other approvals, as applicable. Advisors Moelis & Company and NovaOne acted as financial advisors for Torrent. Khaitan & Co. acted as legal counsel to Torrent. Ernst and Young Merchant Banking Services LLP (for Torrent) and BDO Valuation Advisory LLP (for JB Pharma) acted as independent registered valuers. Kotak Investment Banking and Rothschild & Co acted as financial advisors to KKR. Shardul Amarchand Mangaldas & Co acted as legal counsel to KKR and JB Pharma. Goldman Sachs (India) Securities Pvt. Ltd. acted as the financial advisor to JB Pharma. AZB & Partners acted as legal counsel to the Board of Directors of JB Pharma. Fairness opinion on the share exchange ratio recommended by the valuer was provided by Axis Capital Limited to the Board of Torrent and by ICICI Securities Limited to the Board of JB Pharma. About Torrent Torrent Pharma is a leading player in the Indian pharmaceutical sector, concentrating on the chronic and sub-chronic therapeutic segments. The Company has established itself as a leader in developing niche pharmaceutical solutions through its patient-centric innovation. It also has a strong global presence across Brazil, Germany, and the United States. About JB Pharma J.B. Pharma (BSE: 506943 | NSE: JBCHEPHARM | ISIN: INE572A01028), is one of the fastest growing pharmaceutical companies in India and a leading player in the hypertension segment. Besides its strong India presence, which accounts for majority of its revenue, its other two home markets are Russia and South Africa. In India, the company has six brands among the top 300 IPM brands in the country. The company exports its finished formulations to over 40 countries including the USA, and is also a leading CDMO player in the segment of medicated lozenges. It has eight state of the art manufacturing facilities in India including a dedicated manufacturing facility for lozenges. The manufacturing facilities are certified by leading regulators across the world. About KKR KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR's insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR's investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR's website at For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group's website at
Business Upturn
19 hours ago
- Business Upturn
What is operating leverage? Simple explanation with Indian examples
Operating leverage is one of the most important, yet often misunderstood, financial concepts for Indian investors. If you've ever wondered why some companies see a sharp rise in profits when sales go up, the answer lies in operating leverage. Let's break it down with simple language and Indian business examples. Advertisement What is operating leverage? Operating leverage measures how sensitive a company's operating profit (EBIT) is to a change in sales. In simple terms: High operating leverage = Small increase in sales leads to a big increase in profit Low operating leverage = Profits grow slowly even if sales rise It all depends on a company's fixed costs vs variable costs. Fixed costs vs variable costs – the basics Fixed costs: Expenses that stay constant, no matter how much the company produces or sells. Example: Factory rent for Tata Motors or advertising budget for Hindustan Unilever. Variable costs: Costs that increase as production increases. Example: Raw materials for Marico or packaging costs for Dabur. A company with high fixed costs and low variable costs has high operating leverage. Simple example of operating leverage (using Indian context) Let's say a company like Page Industries (Jockey India) spends heavily on advertising, salaries, and manufacturing infrastructure. These are fixed costs. If sales increase by 20%, profits could jump 50% or more. Why? Because the fixed costs stay the same, and the extra sales mostly go towards profits. On the flip side, if sales fall, profits can drop sharply. Why Indian investors should care about operating leverage Operating leverage helps you predict how profits will move with sales changes. In good times: High operating leverage companies can deliver multi-quarter profit growth. In bad times: These same companies suffer more because their fixed costs remain high. Example: During a consumption slowdown, companies like Titan or Avenue Supermarts (DMart) may face profit pressure if their fixed expenses are not covered by lower sales. How to check a company's operating leverage (quick method) Look at EBIT growth vs Revenue growth over past quarters. If EBIT grows faster than revenue, the company has high operating leverage. Focus on sectors with naturally high operating leverage: Examples include automobiles, FMCG, retail, and capital goods. Final takeaway Understanding operating leverage helps Indian retail investors spot companies that can deliver outsized profit growth during a demand upswing. But remember, it also comes with higher risk during slowdowns. Before investing, always check both revenue trends and fixed cost structures.
